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Anti-tumor specific immune responses are modulated
during tumor development via different escape mecha-
nisms abrogating the process of effective immunological
tumor destruction. In this study we analyzed the p53 spe-
cific immune response in colorectal cancer patients (n =
24) depending on their UICC stage and characterized
their regulatory T cell functions independent of the p53
mutational status.
Peripheral blood lymphocytes (PBMCs) from patients
(UICC-stage I-IV) were stimulated with 10 pools of syn-
thetic overlapping p53 peptides encompassing the full
length wild-type (wt) p53 sequence and Il-10 and IFN-γ
expression was assessed (ELISA and ELISPOT). PBMCs
and tumor specific cells as well as tumor specimens of
those patients were further characterized (cytospins,
immunofluorescence/histology) and the expression of the
following gene classes were analyzed: CD4, CD25, Foxp3,
GITR, and GATA-3. After stimulation of the lymphocytes
with the peptide pools distinct residues were found that
induced a Th2 (IL-10, n = 24) or Th1 (IFN-γ, n = 10) type
response. T cells from patients in UICC III (n = 7) and IV
(n = 7) expressed higher IL-10 levels in response to p53
peptide (residues 291–330) than patients in UICC I and II
(n = 6) (26 and 62 spots/105 cells versus 14 spots/105
cells, respectively), indicating that the UICC stage may
play a crucial role in IL-10 production in response to p53
peptides. In contrast, other p53 peptides (residues 331–
370) led to IFN-γ production but no correlation was
observed between the UICC stage and the Th1 response.
Markedly elevated amounts of CD4+ CD25+ cells in the
PBMCs, as well as intensified staining for p53 (clone DO-
7) within the tumor were observed in patients expressing
higher levels of IL-10. Comparison of all tumor tissues
using hierarchical clustering analysis showed a Th2 gene
pattern. Dissimilarity between the tissues was due to dif-
ferences in the tumor stage. Within the whole p53 protein
sequence comparably more determinants inducing a Th2
type immune response were observed suggesting that the
type of the tumor specific immune response to p53
depends on presentation and recognition of specific wt
p53 residues. Furthermore, the level of IL-10 production
seems to overweigh the IFN-γ production indicating that
specific p53 epitopes may directly influence the outcome
of immunological surveillance in colorectal cancer
patients. This study offers new insights in a possible mech-
anism facilitating the tumor to escape immune surveil-
lance by inducing rather a Th2 type (tolerance) than Th1
type response (destruction) through p53 overexpression.
from Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2nd Annual Meeting
Mainz, Germany, 6–7 May 2004
Published: 1 July 2004
Cancer Cell International 2004, 4(Suppl 1):S26
Received: 28 April 2004
<supplement> <title> <p>Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2<sup>nd </sup>Annual Meeting</p> </title> <note>Meeting abstracts</note> </supplement>
This article is available from: http://www.cancerci.com/content/4/S1/S26
